Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NiCord Transplantation in Hematological Malignancies
NCT01816230Phase 2Completed
- Sponsor
- Gamida Cell
- Start
- Apr 2013
- Primary completion
- Jun 2017
- Modality
- Stem Cell Therapies
- Countries
- 5
01
Overview
A Phase 2 trial of omidubicel in hematological malignancies, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Gamida Cell. Started Apr 2013; status: completed.
02
Drugs
omidubicel
03
Conditions
hematological malignanciesacute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01816230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01816230.